Get it on Google Play

Roche reports Phase 3 data on sefaxersen for kidney disease

October 23, 2026 1:37 PM EDT Send to a Friend
Roche announced Phase 3 trial results for investigational drug sefaxersen, showing a statistically significant 43.1% reduction in proteinuria relative to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login